Listen to this story
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThis audio file is brought to you by 
0:00
0:00
Loading audio file, please wait.
Eli Lilly and Co. may have found a new use for its osteoporosis drug Evista, according to Bloomberg.
The U.S. Food and Drug Administration said Evista reduced the risk of certain invasive breast cancers in post-menopausal women.
However, studies from Indianapolis-based Lilly provided weaker support for Evista’s ability to help women at high risk of developing breast cancer, the FDA said.
Evista is a $1 billion a year drug, but Lilly wants to find new uses for it because analysts expect its sales to tail off gradually over the next several years. Lilly has a patent on Evista until 2014.
Please enable JavaScript to view this content.